Skip to main content
OpenTrials
Completed

NCT Number: NCT06800885

Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants

Real-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase vaccination coverage.

This study aims to address the gap by assessing current influenza vaccination rates, particularly among those aged 60 and older, to inform public health interventions and encourage healthcare providers to recommend influenza vaccination more proactively.

The primary objective of this study is to determine the influenza vaccination rates in the German population during the current respiratory season. The study will focus on:

1. Assessing the vaccination rates among the two main age groups 18 years of age through and including 59 years of age and 60 years of age (inclusive) and older 2. Assessing the vaccination rate among individuals with risk-based vaccination recommendation according to Standing Committee on Vaccination (Ständige Impfkommission) (STIKO) The study will target a disproportionate sample of the German population regarding age: 30% aged 18 years of age through and including 59 year of age and 70% aged 60 years of age (inclusive) and older. Within these age groups, the study targets a representative distribution regarding gender and region.

This study is conducted as an online survey that will either be self-completed by the respondents (CAWI) or completed via an interviewer for a subgroup of respondents aged 70+ (CATI). The survey is estimated to last 10 minutes and will comprise of closed-ended questions only (i.e., respondents will not have the possibility to add any free-text). The survey will be conducted in German.

The panelists will be divided into strata based on demographic variables like gender and region. Within each stratum, participants will be randomly selected to participate in the survey.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza Immunization Infections Influenza, Human Orthomyxoviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Germany

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Reside in Germany at the time of survey completion
  • Be at least 18 years old at the time of survey completion.
  • Agree with privacy policy and AE (Adverse Event) reporting requirements before proceeding with the survey.
  • Read and agree to the ICF (Informed Consent Form) by ticking a box before proceeding with the survey or telephone interview.

Exclusion criteria

  • Participation in the study (= completed the survey or telephone interview) in a previous wave of the current season.
  • Living in nursing home Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Treatment and study plan

Primary outcomes

  1. Assessing the seasonal influenza vaccination rates among diverse healthy participants 18 years of age through and including 59 years of age

    Time frame: Throughout Study (Approximately 3 months)

    Descriptive analysis of vaccination status (yes/no) will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in the age group 18 years of age to and including 59 years of age

  2. Assessing the seasonal influenza vaccination rates among diverse healthy participants 18 years through and including 34 years of age

    Time frame: Throughout Study (Approximately 3 months)

    Descriptive analysis of vaccination status (yes/no) will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in the age group 18 years of age through 34 years of age

  3. Assessing the seasonal influenza vaccination rates among pregnant women (with or without co-morbidities)

    Time frame: Throughout Study (Approximately 3 months)

    Descriptive analysis of vaccination status (yes/no) will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in pregnant women with or without co-morbidities

  4. Assessing the seasonal influenza vaccination rates among diverse patients with chronic illness

    Time frame: Throughout Study (Approximately 3 months)

    Descriptive analysis of vaccination status (yes/no) will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in diverse patients with chronic illness

  5. Assessing the seasonal influenza vaccination rates among diverse healthy participants 35 years through and including 59 years of age

    Time frame: Throughout Study (Approximately 3 months)

    Descriptive analysis of vaccination status (yes/no) will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in the age group 35 years of age through and including 59 years of age

  6. Assessing the seasonal influenza vaccination rates among diverse healthy participants 18 years through and including 59 years of age

    Time frame: Throughout Study (Approximately 3 months)

    Descriptive analysis of vaccination status (yes/no) will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in the age group 18 years of age through and including 59 years of age

  7. Assessing the seasonal influenza vaccination rates among diverse healthy participants older than 60 years of age

    Time frame: Throughout Study (Approximately 3 months)

    Descriptive analysis of vaccination status (yes/no) will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in the older than 60 years of age group

  8. Assessing the seasonal influenza vaccination rates among diverse healthy participants aged 60 years of age through and including 69 years of age

    Time frame: Throughout Study (Approximately 3 months)

    Descriptive analysis of vaccination status (yes/no) will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in the age group 60 years of age through and including 69 years of age

  9. Assessing the seasonal influenza vaccination rates among diverse healthy participants aged 70 years of age through and including 79 years of age

    Time frame: Throughout Study (Approximately 3 months)

    Descriptive analysis of vaccination status (yes/no) will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in the age group 70 years of age through and including 79 years of age

  10. Assessing the seasonal influenza vaccination rates among diverse healthy participants older than 80 years of age

    Time frame: Throughout Study (Approximately 3 months)

    Descriptive analysis of vaccination status (yes/no) will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in the older than 80 years of age group

Secondary outcomes

  1. Assessing the seasonal evolution of the influenza vaccination coverage rates (VCR) among the two main age groups 18 years of age through and including 59 years of age and 60 years of age and older (inclusive)

    Time frame: Throughout Study (approxmatley 3 months)

    Descriptive analysis of VCR by time of survey during the season (as proportion of vaccinated individuals among all enrolled persons per wave in the two main age groups 18 year of age through and including 59 years of age and 60 years of age (inclusive) and older, and per subgroup/strata)

  2. Assessing the seasonal evolution of the influenza vaccination coverage rates (VCR) through time trends among the two main age groups 18 years of age through and including 59 years of age and 60 years of age and older (inclusive)

    Time frame: Throughout Study (approxmatley 3 months)

    Analysis of time trends over the three seasons, based on VCR data collected in January of each year (last wave) (as proportion of vaccinated individuals among all enrolled persons per wave in the two main age groups 18 year of age through and including 59 years of age and 60 years of age (inclusive) and older, and per subgroup/strata)

  3. Assessing reasons for/against influenza vaccination in the target population of the STIKO recommendation for each season

    Time frame: Throughout study (approximatley 3 months)

    Descriptive analysis of vaccination status (yes/no) and reasons for or against influenza vaccination will be performed using summary statistics, i.e., proportion of vaccinated individuals among all enrolled persons per wave in the two main age groups 18 year of age through and including 59 years of age and 60 years of age (inclusive) and older, and per subgroup/strata)

  4. Assess the reliability of a demographic study based on randomly sampled population groups using Computer-Assisted Web Interview (CAWI) for estimating VCR

    Time frame: Throughout the study (approximatley 3 months)

    Descriptive analysis of VCR (proportions) for the two main age groups 18 years of age through 59 and 60 years (inclusive) of age and older and per subgroup/strata) in comparison with results from the Robert Koch-Institute (RKI) vaccination surveillance

  5. Compare the reliability of VCR estimates in the elderly population (70+ years) obtained through a mixed approach of CAWI and Computer assisted telephone interview (CATI) versus CAWI only (in the first season)

    Time frame: Throughout the study (approximatley 3 months)

    Descriptive analysis of VCR (proportions) in the regions with mixed mode data collection approach in comparison with other regions and with results from the RKI vaccination surveillance for age group 70 years of age and older

Sponsors and collaborators

Lead sponsor

Sanofi Pasteur, a Sanofi Company

Industry

Registry information

Official study title

Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants During Current Respiratory Season

Acronym: Vakzimeter FLU

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jan 30, 2025
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.